| scholarly article | Q13442814 |
| P50 | author | Lukas Pezawas | Q42305729 |
| P2093 | author name string | Markus Müller | |
| Christian Scharinger | |||
| Ulrich Rabl | |||
| P2860 | cites work | Neuronal effects of acute citalopram detected by pharmacoMRI. | Q46486553 |
| MAO A VNTR polymorphism and variation in human morphology: a VBM study. | Q46505844 | ||
| Variation of human amygdala response during threatening stimuli as a function of 5'HTTLPR genotype and personality style | Q46543887 | ||
| Brain derived neurotrophic factor Val66Met polymorphism, the five factor model of personality and hippocampal volume: Implications for depressive illness | Q46544374 | ||
| Dose-dependent effect of the Val66Met polymorphism of the brain-derived neurotrophic factor gene on memory-related hippocampal activity. | Q46577196 | ||
| Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. | Q46592697 | ||
| Serotonin transporter gene polymorphisms and sertraline response in major depression patients | Q46615025 | ||
| Monoamine oxidase A-uVNTR genotype affects limbic brain activity in response to affective facial stimuli | Q46664376 | ||
| Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression? | Q46665189 | ||
| Additive effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on neural correlates of affective processing | Q46722737 | ||
| Impact of catechol-O-methyltransferase Val(108/158) Met genotype on hippocampal and prefrontal gray matter volume | Q46743546 | ||
| Genetically dependent modulation of serotonergic inactivation in the human prefrontal cortex. | Q46762906 | ||
| Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy | Q46769754 | ||
| The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. | Q46837612 | ||
| Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin | Q46852500 | ||
| The Val66Met polymorphism of the brain-derived neurotrophic factor gene affects age-related brain morphology | Q46876182 | ||
| SERT-ainly involved in depression, but when? | Q46877832 | ||
| Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran | Q46893457 | ||
| Functional coupling of the amygdala in depressed patients treated with antidepressant medication | Q46911638 | ||
| BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects | Q46915507 | ||
| Antidepressant drug treatment modifies the neural processing of nonconscious threat cues | Q46929906 | ||
| Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study | Q46974112 | ||
| The effects of escitalopram on working memory and brain activity in healthy adults during performance of the n-back task | Q46981940 | ||
| Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder | Q46990953 | ||
| BDNF, relative preference, and reward circuitry responses to emotional communication | Q47958150 | ||
| Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression | Q48118611 | ||
| Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration | Q21092366 | ||
| What we can do and what we cannot do with fMRI | Q22122223 | ||
| A comprehensive review of genetic association studies | Q22337119 | ||
| Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease | Q22337234 | ||
| Efficacy of antidepressants in adults | Q24555325 | ||
| 5-HT(1A) receptor function in major depressive disorder | Q24643511 | ||
| Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic | Q24647348 | ||
| The molecular neurobiology of depression | Q24656261 | ||
| A genomewide association study of citalopram response in major depressive disorder | Q24656746 | ||
| Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior | Q24679793 | ||
| Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT(2C) receptor antagonist | Q24684698 | ||
| Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes | Q27115017 | ||
| The personality trait openness is related to cerebral 5-HTT levels | Q27115023 | ||
| Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene | Q27860482 | ||
| Long story short: the serotonin transporter in emotion regulation and social cognition | Q27863369 | ||
| Voxel-based morphometry–the methods | Q28138780 | ||
| The endophenotype concept in psychiatry: etymology and strategic intentions | Q28187744 | ||
| Is mood chemistry? | Q28237445 | ||
| Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response | Q28256653 | ||
| Neurobiological and clinical effects of the antidepressant tianeptine | Q28260673 | ||
| Intermediate phenotypes and genetic mechanisms of psychiatric disorders | Q28264588 | ||
| Psychiatric genetics: progress amid controversy | Q28284253 | ||
| A functional polymorphism in the monoamine oxidase A gene promoter | Q28287498 | ||
| The orbitofrontal cortex and beyond: from affect to decision-making | Q28295451 | ||
| Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region | Q28297391 | ||
| Essential role of brain-derived neurotrophic factor in adult hippocampal function | Q28593001 | ||
| Differences in Brain Glucose Metabolism Between Responders to CBT and Venlafaxine in a 16-Week Randomized Controlled Trial | Q29028866 | ||
| Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. | Q29417150 | ||
| Genetic mapping in human disease | Q29614943 | ||
| Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice | Q29614979 | ||
| The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function | Q29615582 | ||
| Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action | Q29615696 | ||
| A neurotrophic model for stress-related mood disorders | Q29616291 | ||
| Serotonin transporter genetic variation and the response of the human amygdala | Q29617804 | ||
| 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression | Q29618835 | ||
| A default mode of brain function: a brief history of an evolving idea | Q29619033 | ||
| Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis | Q29619093 | ||
| Imaging phenotypes of major depressive disorder: genetic correlates | Q30478592 | ||
| Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories | Q30482565 | ||
| What's new in neuroimaging methods? | Q30488026 | ||
| Human fear conditioning and extinction in neuroimaging: a systematic review | Q30489073 | ||
| Cognitive impact of genetic variation of the serotonin transporter in primates is associated with differences in brain morphology rather than serotonin neurotransmission. | Q30494258 | ||
| Hippocampal volume and depression: a meta-analysis of MRI studies | Q30974294 | ||
| Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study | Q31028649 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder | Q31121208 | ||
| Assessing human 5-HT function in vivo with pharmacoMRI. | Q31162376 | ||
| A systematic review of diffusion tensor imaging studies in affective disorders | Q33483884 | ||
| Prognostic and diagnostic potential of the structural neuroanatomy of depression | Q33487168 | ||
| Role of variation in the serotonin transporter protein gene (SLC6A4) in trait disturbances in the ventral anterior cingulate in bipolar disorder | Q33679424 | ||
| Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment | Q33688119 | ||
| A genetic variant BDNF polymorphism alters extinction learning in both mouse and human | Q33690935 | ||
| The endophenotype concept in psychiatric genetics | Q33693915 | ||
| Functional and structural connectivity between the perigenual anterior cingulate and amygdala in bipolar disorder | Q33696275 | ||
| Effects of the brain-derived neurotrophic growth factor val66met variation on hippocampus morphology in bipolar disorder | Q33723741 | ||
| Escitalopram effects on insula and amygdala BOLD activation during emotional processing | Q33730062 | ||
| Acute 5-HT reuptake blockade potentiates human amygdala reactivity. | Q33805388 | ||
| Linkage and associated studies of schizophrenia | Q33920492 | ||
| Beyond affect: a role for genetic variation of the serotonin transporter in neural activation during a cognitive attention task | Q33922872 | ||
| Research and treatment approaches to depression | Q33945106 | ||
| A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide | Q33987746 | ||
| HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions | Q48128210 | ||
| Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differences in human personality | Q48159342 | ||
| A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. | Q48166495 | ||
| Genetic variation in serotonin transporter alters resting brain function in healthy individuals | Q48178578 | ||
| A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression | Q48187724 | ||
| Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression | Q48219987 | ||
| Serotonergic genes modulate amygdala activity in major depression | Q48281587 | ||
| Neural and genetic correlates of antidepressant response to sleep deprivation: a functional magnetic resonance imaging study of moral valence decision in bipolar depression | Q48282057 | ||
| Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment | Q48312843 | ||
| Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation | Q48347908 | ||
| The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine | Q48375775 | ||
| Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects | Q48388265 | ||
| Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder | Q48419893 | ||
| fMRI predictors of treatment outcome in pediatric anxiety disorders | Q48421467 | ||
| Hippocampal volume in first episode and recurrent depression | Q48443942 | ||
| COMT genotype influences prefrontal response to emotional distraction | Q48462446 | ||
| Neuroticism modulates amygdala-prefrontal connectivity in response to negative emotional facial expressions. | Q48484334 | ||
| Impact of complex genetic variation in COMT on human brain function | Q48492697 | ||
| The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: incremental support for a genetic risk factor for depression. | Q48680899 | ||
| Subgenual prefrontal cortex abnormalities in mood disorders | Q48725544 | ||
| Cingulate function in depression: a potential predictor of treatment response | Q48768060 | ||
| Depression-related variation in brain morphology over 3 years: effects of stress? | Q48891594 | ||
| Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study | Q48904887 | ||
| Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects | Q48934111 | ||
| Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder | Q48954788 | ||
| Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. | Q48967630 | ||
| The BDNF Val66Met polymorphism affects amygdala activity in response to emotional stimuli: evidence from a genetic imaging study | Q49118049 | ||
| The missing link between clinical endpoints and drug targets in depression | Q50709240 | ||
| Reduced amygdala-prefrontal coupling in major depression: association with MAOA genotype and illness severity. | Q50788443 | ||
| A single dose of citalopram increases fear recognition in healthy subjects. | Q50911547 | ||
| Amygdala reactivity to emotional faces predicts improvement in major depression | Q50960727 | ||
| Pioneering first steps and cautious conclusions | Q51859228 | ||
| Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. | Q51899390 | ||
| Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors | Q51905107 | ||
| The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. | Q51935722 | ||
| Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study | Q54047414 | ||
| A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. | Q54601373 | ||
| Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. | Q55034361 | ||
| The ins and outs of fMRI signals. | Q55044732 | ||
| Allelic Variation of Human Serotonin Transporter Gene Expression | Q55934627 | ||
| Genome-wide association study of recurrent major depressive disorder in two European case–control cohorts | Q57323019 | ||
| Efficacy of Paroxetine in Depression Is Influenced by a Functional Polymorphism Within the Promoter of the Serotonin Transporter Gene | Q58451550 | ||
| Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder | Q59215559 | ||
| The developmental role of serotonin: news from mouse molecular genetics | Q35584090 | ||
| Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. | Q35705858 | ||
| A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression | Q35737324 | ||
| The COMT Val158Met polymorphism and temporal lobe morphometry in healthy adults. | Q35944710 | ||
| Guidelines for reporting an fMRI study | Q36527046 | ||
| Neuroimaging studies of serotonin gene polymorphisms: exploring the interplay of genes, brain, and behavior | Q36547543 | ||
| Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy | Q36600369 | ||
| Glial reduction in the subgenual prefrontal cortex in mood disorders | Q36651128 | ||
| Contrasting roles for cingulate and orbitofrontal cortex in decisions and social behaviour | Q36751353 | ||
| Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression | Q36848923 | ||
| New insights into BDNF function in depression and anxiety | Q36921962 | ||
| Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies | Q36976169 | ||
| The amygdala | Q36980001 | ||
| Genetic association study of BDNF in depression: finding from two cohort studies and a meta-analysis | Q37060401 | ||
| BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation. | Q37061555 | ||
| Variation in dopamine genes influences responsivity of the human reward system | Q37062116 | ||
| Pharmacogenetics in psychiatry: are we ready for widespread clinical use? | Q37076472 | ||
| Ten simple rules for reporting voxel-based morphometry studies. | Q37100032 | ||
| SLC6A4 variation and citalopram response | Q37139300 | ||
| Effect of BDNF val66met polymorphism on age-related amygdala volume changes in healthy subjects | Q37171338 | ||
| A genetically mediated bias in decision making driven by failure of amygdala control | Q37201738 | ||
| Impact of interacting functional variants in COMT on regional gray matter volume in human brain | Q37243074 | ||
| Frontal-limbic white matter pathway associations with the serotonin transporter gene promoter region (5-HTTLPR) polymorphism | Q37286925 | ||
| Effects of HTR1A C(-1019)G on amygdala reactivity and trait anxiety | Q37328993 | ||
| Pharmacogenetics-guided dose modifications of antidepressants | Q37342123 | ||
| Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis | Q37370760 | ||
| Genetic variation in dopaminergic neuromodulation influences the ability to rapidly and flexibly adapt decisions | Q37384016 | ||
| The structural integrity of an amygdala-prefrontal pathway predicts trait anxiety | Q37469424 | ||
| Pharmacogenomics of antidepressant drugs | Q37535096 | ||
| The role of pharmacogenetics in the treatment of depression and anxiety disorders | Q37593913 | ||
| Genetic studies of drug response and side effects in the STAR*D study, part 1. | Q37598385 | ||
| New perspectives on the neurodevelopmental effects of SSRIs | Q37645078 | ||
| Reward and the serotonergic system | Q37683006 | ||
| Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study | Q34101325 | ||
| Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain. | Q34111111 | ||
| Inheritance and drug response | Q34175608 | ||
| The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder | Q34227903 | ||
| Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotype | Q34302202 | ||
| The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings | Q34354633 | ||
| Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice | Q34363151 | ||
| Polymorphism in serotonin transporter gene associated with susceptibility to major depression. | Q34375363 | ||
| A susceptibility gene for affective disorders and the response of the human amygdala | Q34392171 | ||
| Frontal and limbic metabolic differences in subjects selected according to genetic variation of the SLC6A4 gene polymorphism. | Q34413606 | ||
| Sequence analysis of the serotonin transporter and associations with antidepressant response | Q34430697 | ||
| The yin and yang of neurotrophin action | Q34439423 | ||
| Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain | Q34481388 | ||
| Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond | Q34494146 | ||
| The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons | Q34498146 | ||
| Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy | Q34544344 | ||
| Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. | Q34552006 | ||
| Evidence for HTR1A and LHPP as interacting genetic risk factors in major depression | Q34588248 | ||
| A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants | Q34594119 | ||
| Neural mechanisms of genetic risk for impulsivity and violence in humans | Q34597413 | ||
| Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study. | Q34599330 | ||
| Midbrain serotonin transporter binding potential measured with [11C]DASB is affected by serotonin transporter genotype | Q34602395 | ||
| Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression | Q34614619 | ||
| 5-HTTLPR biases amygdala activity in response to masked facial expressions in major depression. | Q34615479 | ||
| Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder | Q34658088 | ||
| Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea | Q34662897 | ||
| Is it time to reassess the BDNF hypothesis of depression? | Q34663655 | ||
| Meta-analyses of genetic studies on major depressive disorder | Q34701323 | ||
| The genetic basis of variability in drug responses | Q34741545 | ||
| Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response | Q34743434 | ||
| Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression | Q34762522 | ||
| The effects of gender and COMT Val158Met polymorphism on fearful facial affect recognition: a fMRI study | Q34829033 | ||
| Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder | Q34871885 | ||
| Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in recognition of citalopram and tricyclic antidepressants. | Q34943864 | ||
| Neural mechanisms of a genome-wide supported psychosis variant | Q34978645 | ||
| Neural correlates of epigenesis | Q35070669 | ||
| Neurobiology of emotion perception I: The neural basis of normal emotion perception | Q35208701 | ||
| Neurobiology of emotion perception II: Implications for major psychiatric disorders | Q35208704 | ||
| Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response | Q45077786 | ||
| Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing | Q45133109 | ||
| Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression | Q45134204 | ||
| The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression | Q45134478 | ||
| Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter | Q45183612 | ||
| Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression | Q45277258 | ||
| Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram | Q45280761 | ||
| Moderation of antidepressant response by the serotonin transporter gene. | Q45945437 | ||
| Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1. | Q45993661 | ||
| 5-HTT genotype effect on prefrontal-amygdala coupling differs between major depression and controls. | Q46039998 | ||
| Neural connectivity as an intermediate phenotype: brain networks under genetic control | Q46084580 | ||
| Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression | Q46094498 | ||
| Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response | Q46112497 | ||
| Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder | Q46191111 | ||
| Meta-analysis of the brain-derived neurotrophic factor gene (BDNF) Val66Met polymorphism in anxiety disorders and anxiety-related personality traits | Q46194967 | ||
| Reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression | Q46246967 | ||
| The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting | Q46260465 | ||
| Disturbances in selective information processing associated with the BDNF Val66Met polymorphism: evidence from cognition, the P300 and fronto-hippocampal systems | Q46329587 | ||
| Serotonergic genes and amygdala activity in response to negative affective facial stimuli in Korean women | Q46338998 | ||
| Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. | Q46423759 | ||
| The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study | Q46435454 | ||
| False positives in imaging genetics | Q38428130 | ||
| Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder. | Q38435480 | ||
| Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. | Q39267836 | ||
| A longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapy | Q39273165 | ||
| Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder | Q39967504 | ||
| Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity | Q40036871 | ||
| Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients | Q40084075 | ||
| Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. | Q40370839 | ||
| Fluoxetine (Prozac) binding to serotonin transporter is modulated by chloride and conformational changes | Q41536585 | ||
| Reciprocal effects of antidepressant treatment on activity and connectivity of the mood regulating circuit: an FMRI study | Q42074509 | ||
| Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study | Q43260686 | ||
| Postnatal handling reverses social anxiety in serotonin receptor 1A knockout mice. | Q43279177 | ||
| No association of the Val66Met polymorphism of the brain-derived neurotrophic factor with hippocampal volume in major depression | Q43294900 | ||
| 'Negativity bias' in risk for depression and anxiety: brain-body fear circuitry correlates, 5-HTT-LPR and early life stress | Q43429980 | ||
| Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression | Q43581037 | ||
| Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings | Q43670285 | ||
| Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression | Q43728696 | ||
| Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. | Q43870679 | ||
| Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. | Q43920402 | ||
| Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult | Q43937540 | ||
| Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome | Q43975771 | ||
| How can we realize the promise of personalized antidepressant medicines? | Q44045526 | ||
| Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies | Q44066592 | ||
| Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter | Q44091008 | ||
| No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment | Q44123578 | ||
| Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism | Q44239950 | ||
| Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders | Q44245157 | ||
| Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder | Q44262062 | ||
| The neural substrates of affective processing in depressed patients treated with venlafaxine | Q44265275 | ||
| Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders | Q44389129 | ||
| No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. | Q44398449 | ||
| Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment | Q44628316 | ||
| Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response | Q44634481 | ||
| Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline | Q44646503 | ||
| 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study | Q44659875 | ||
| Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression | Q44710961 | ||
| Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention. | Q44733600 | ||
| Investigation of serotonin-related genes in antidepressant response | Q44820568 | ||
| Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression | Q44906816 | ||
| Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment | Q44914000 | ||
| The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine | Q44926896 | ||
| Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition | Q44960127 | ||
| Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders | Q44993055 | ||
| Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. | Q45036983 | ||
| Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study | Q45047364 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 471-489 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | Expert Review of Clinical Pharmacology | Q15793519 |
| P1476 | title | Imaging genetics: implications for research on variable antidepressant drug response | |
| P478 | volume | 3 |
| Q30657759 | A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities |
| Q51839583 | Imaging genetics: Progressing by leaps and bounds |
| Q37801313 | Is there a personalized medicine for mood disorders? |
| Q38983579 | Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies. |
| Q27011768 | Use of magnetic resonance imaging in pharmacogenomics |
Search more.